Literature DB >> 7402590

Adverse reactions from timolol administration.

E M Van Buskirk.   

Abstract

Five hundred forty-seven reports of adverse reactions to timolol maleate received by the National Registry for Drug-induced Ocular Side Effects during an eleven-month period were reviewed. Approximately half the reports concerned systemic reactions affecting the cardiac, pulmonary, central nervous, gastrointestinal, and dermatologic systems. Most serious were depression, anxiety, and confusion; bradycardia and arrhythmias; and pulmonary airway obstruction. Half of the ocular side effects concerned external ocular disease, of which superficial punctate keratitis and corneal anesthesia were the most remarkable. Ten percent of the reports described a visual disturbance which, in many cases, was not associated with refractive error.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7402590     DOI: 10.1016/s0161-6420(80)35215-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  57 in total

1.  Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone.

Authors:  J Shimazaki; K Hanada; Y Yagi; J Yamagami; M Ishioka; S Shimmura; K Tsubota
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

Review 2.  Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? The controversy.

Authors:  I Goldberg
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

3.  Effects of long-term topical anti-glaucoma medications on meibomian glands.

Authors:  Reiko Arita; Kouzo Itoh; Shuji Maeda; Koshi Maeda; Ayumu Furuta; Atsuo Tomidokoro; Makoto Aihara; Shiro Amano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-18       Impact factor: 3.117

Review 4.  Chronic open-angle glaucoma. Review for primary care physicians.

Authors:  Feisal A Adatia; Karim F Damji
Journal:  Can Fam Physician       Date:  2005-09       Impact factor: 3.275

Review 5.  Evolving paradigms in the medical treatment of glaucoma.

Authors:  John S Cohen; Anup K Khatana; Linda J Greff
Journal:  Int Ophthalmol       Date:  2006-03-07       Impact factor: 2.031

Review 6.  Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery.

Authors:  Abeer M Al-Ghananeem; Peter A Crooks
Journal:  Molecules       Date:  2007-03-08       Impact factor: 4.411

7.  Ophthalmology-Important Advances in Clinical Medicine: Severe Systemic Effects From Topically Applied beta-Adrenergic Blocking Agents.

Authors:  A J Flach
Journal:  West J Med       Date:  1984-02

8.  Tensioactivity and supramolecular organization of the palmitoyl prodrug of timolol.

Authors:  B Pech; J E Proust; Y Bouligand; J P Benoit
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

9.  Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients.

Authors:  M L Vuori; T Kaila
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-03       Impact factor: 3.117

Review 10.  Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.

Authors:  A M Brooks; W E Gillies
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.